Michael Schmidt
Stock Analyst at Guggenheim
(3.45)
# 951
Out of 4,761 analysts
86
Total ratings
50%
Success rate
5.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRUS Merus | Reiterates: Buy | n/a | $47.37 | - | 3 | Feb 12, 2025 | |
| EXEL Exelixis | Reiterates: Buy | $42 | $36.85 | +13.98% | 10 | Feb 12, 2025 | |
| ARVN Arvinas | Reiterates: Buy | $57 | $17.77 | +220.77% | 3 | Feb 12, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Buy | n/a | $7.68 | - | 4 | Feb 10, 2025 | |
| VSTM Verastem | Reiterates: Buy | n/a | $5.68 | - | 2 | Jan 24, 2025 | |
| IPSC Century Therapeutics | Reiterates: Buy | n/a | $0.73 | - | 1 | Jan 22, 2025 | |
| SWTX SpringWorks Therapeutics | Maintains: Buy | $80 → $78 | $58.25 | +33.91% | 1 | Jan 8, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Buy | $10 | $1.63 | +513.50% | 3 | Dec 12, 2024 | |
| BPMC Blueprint Medicines | Reiterates: Buy | n/a | $92.25 | - | 2 | Dec 11, 2024 | |
| TARA Protara Therapeutics | Reiterates: Buy | $20 | $3.72 | +437.63% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $87 | $41.34 | +110.45% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $2.32 | +244.83% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $0.56 | +436.19% | 2 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $29.92 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $92 | $72.11 | +27.58% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.75 | +220.00% | 1 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.49 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $9.52 | +267.65% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.76 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 | $0.53 | +1,212.83% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.17 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $15.74 | +116.01% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $42 | $16.38 | +156.41% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $0.97 | +1,954.65% | 3 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $22.34 | - | 2 | Jan 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.41 | +1,673.05% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $6.22 | +382.32% | 1 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $2.64 | +884.85% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.53 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.08 | - | 4 | Mar 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $35.22 | +127.14% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.59 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $3.42 | +60.82% | 2 | Nov 7, 2017 |
Merus
Feb 12, 2025
Reiterates: Buy
Price Target: n/a
Current: $47.37
Upside: -
Exelixis
Feb 12, 2025
Reiterates: Buy
Price Target: $42
Current: $36.85
Upside: +13.98%
Arvinas
Feb 12, 2025
Reiterates: Buy
Price Target: $57
Current: $17.77
Upside: +220.77%
ORIC Pharmaceuticals
Feb 10, 2025
Maintains: Buy
Price Target: n/a
Current: $7.68
Upside: -
Verastem
Jan 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $5.68
Upside: -
Century Therapeutics
Jan 22, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.73
Upside: -
SpringWorks Therapeutics
Jan 8, 2025
Maintains: Buy
Price Target: $80 → $78
Current: $58.25
Upside: +33.91%
ADC Therapeutics
Dec 12, 2024
Reiterates: Buy
Price Target: $10
Current: $1.63
Upside: +513.50%
Blueprint Medicines
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $92.25
Upside: -
Protara Therapeutics
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $3.72
Upside: +437.63%
Dec 3, 2024
Maintains: Buy
Price Target: $82 → $87
Current: $41.34
Upside: +110.45%
Nov 15, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $2.32
Upside: +244.83%
Nov 15, 2024
Maintains: Buy
Price Target: $4 → $3
Current: $0.56
Upside: +436.19%
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $29.92
Upside: -
Sep 16, 2024
Maintains: Buy
Price Target: $86 → $92
Current: $72.11
Upside: +27.58%
Aug 28, 2024
Initiates: Buy
Price Target: $12
Current: $3.75
Upside: +220.00%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.49
Upside: -
Apr 15, 2024
Initiates: Buy
Price Target: $35
Current: $9.52
Upside: +267.65%
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.76
Upside: -
Feb 29, 2024
Upgrades: Buy
Price Target: $7
Current: $0.53
Upside: +1,212.83%
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.17
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $15.74
Upside: +116.01%
Jul 25, 2023
Maintains: Buy
Price Target: $40 → $42
Current: $16.38
Upside: +156.41%
Jun 27, 2023
Downgrades: Neutral
Price Target: $20
Current: $0.97
Upside: +1,954.65%
Jan 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $22.34
Upside: -
Aug 10, 2021
Initiates: Buy
Price Target: $25
Current: $1.41
Upside: +1,673.05%
Jul 19, 2021
Initiates: Buy
Price Target: $30
Current: $6.22
Upside: +382.32%
May 18, 2021
Initiates: Buy
Price Target: $26
Current: $2.64
Upside: +884.85%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.53
Upside: -
Mar 5, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $4.08
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $35.22
Upside: +127.14%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $6.59
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $3.42
Upside: +60.82%